Anti-VEGF Market to Expand at 4.0% CAGR Through 2032, Driven by Advancements in Ophthalmology and Oncology - Persistence Market Research

The global Anti-Vascular Endothelial Growth Factor (Anti-VEGF) market was valued at US$ 25.2 billion in 2025 and is projected to grow at a CAGR of 4.0%, reaching US$ 33.1 billion by 2032, according to Persistence Market Research. This growth trajectory has been largely influenced by the rising burden of cancer and ocular diseases globally, as well as continuous advancements in biologics and drug delivery systems. Anti-VEGF therapies are a form of targeted treatment that inhibit the vascular endothelial growth factor, effectively restricting the blood supply to cancerous tumors and ocular neovascularizations, resulting in disease control and enhanced patient outcomes.

Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.persistencemarketresearch.com/samples/33422

Among product types, biologics dominate the market, accounting for a 73.3% share in 2024, owing to their high efficacy, specificity, and longer half-life. Geographically, the United States leads the anti-VEGF market, representing 95.2% of the North American market in 2024. This dominance is supported by the nation's high cancer incidence, strong healthcare infrastructure, presence of leading pharmaceutical companies, and access to advanced therapies. Additionally, rapid market growth is observed in China, fueled by favorable government healthcare policies and the inclusion of VEGF inhibitors in national insurance schemes.

✦ Key Highlights from the Report

✦ Anti-VEGF market is expected to grow from US$ 25.2 billion in 2025 to US$ 33.1 billion by 2032.
✦ Biologics accounted for 73.3% of the global market share in 2024.
✦ VEGF-A inhibitors held the highest share at 49.1% in 2024.
✦ Oncology remains the dominant application, contributing 95.5% to market share in 2024.
✦ The United States held 95.2% of the North American market for anti-VEGF drugs.
✦ China represented 48.7% of the East Asia market due to increased healthcare spending.

Market Segmentation 🔄

The anti-VEGF market is segmented based on product type, application, and end user.

By product type, biologics dominate due to their superior specificity and longer action. VEGF-A inhibitors, such as bevacizumab, ranibizumab, and aflibercept, are widely used for their proven efficacy in treating multiple cancers and retinal diseases. Biosimilars are also making headway, driven by their cost-effectiveness and increasing regulatory approvals globally.

By application, oncology leads the market as VEGF inhibitors are central to managing various cancers, including kidney, colorectal, and lung cancers. The ophthalmology segment is also growing rapidly, particularly in treating age-related macular degeneration and diabetic macular edema.

By end user, hospitals represent the largest segment, owing to advanced facilities for cancer treatment and biologics administration. Specialty clinics and ambulatory surgical centers are also key users, especially in ophthalmic applications where intravitreal injections are common.

Read More In Detail: https://www.persistencemarketresearch.com/market-research/anti-vegf-market.asp

🌍 Regional Insights

The North American region, led by the United States, dominates the global anti-VEGF market. This is attributed to a robust healthcare infrastructure, a high incidence of cancer and ocular diseases, and the presence of key market players. The U.S. healthcare system supports the adoption of costly biologics, while regulatory approvals further bolster the introduction of new biosimilars.

In East Asia, China emerges as a rapidly growing market, holding 48.7% of the regional share in 2024. Government healthcare reforms and inclusion of anti-VEGF drugs in the National Reimbursement Drug List have made treatments more accessible to the general population. Additionally, an aging population and rising cancer burden contribute to increased demand.

Oceania, particularly Australia, is seeing steady demand growth due to the increasing use of combination therapies in oncology. Regulatory support from the Therapeutic Goods Administration and the availability of approved VEGF inhibitors enhance market accessibility and innovation.

🚀 Market Drivers

One of the primary market drivers is the growing global prevalence of cancer and retinal diseases, which has increased the demand for targeted treatments like VEGF inhibitors. The rising number of regulatory approvals, especially for biosimilars, is another key driver, enabling companies to introduce cost-effective yet efficient alternatives in the market. The development of advanced drug delivery systems, such as dendrimer-based formulations and liposome intravitreal injections, ensures prolonged and controlled release, enhancing treatment efficacy and reducing patient burden.

⚠️ Market Restraints

The high cost of biologics, particularly approved VEGF inhibitors like aflibercept and ranibizumab, poses a significant barrier to widespread adoption, especially in developing regions. Adverse side effects, including bleeding and thrombotic complications, have raised concerns among healthcare professionals and patients. Additionally, the availability of off-label, low-cost alternatives, such as bevacizumab, may cannibalize market share from approved branded drugs.

✨ Market Opportunities

The market presents notable opportunities in the form of expanding clinical trials for novel indications, including rare cancers and emerging retinal diseases. There is also potential in emerging markets like India, Brazil, and Southeast Asia, where improving healthcare infrastructure and increasing healthcare investments open doors for new entrants. Additionally, the growing preference for combination therapies that integrate VEGF inhibitors with immunotherapy or chemotherapy is expected to drive demand and innovation.

Do You Have Any Query Or Specific Requirement? Request Customization of Report: https://www.persistencemarketresearch.com/request-customization/33422

❓ Frequently Asked Questions (FAQs)

How Big is the Anti-VEGF Market globally?
Who are the Key Players in the Global Market for Anti-VEGF drugs?
What is the Projected Growth Rate of the Anti-VEGF Market until 2032?
What is the Market Forecast for Anti-VEGF products for 2032?
Which Region is Estimated to Dominate the Anti-VEGF Industry through the Forecast Period?

Company Insights

• Pfizer Inc.
• Bayer AG
• Novartis AG
• Sanofi SA
• Exelixis Inc.
• Eisai Co. Ltd.
• Amgen Inc.
• F. Hoffmann-La Roche Ltd.
• Eli Lilly and Company
• Amneal Pharmaceuticals Inc.
• Jiangsu Hengrui Pharmaceuticals Co. Ltd.
• Takeda Pharmaceutical Co. Ltd
• Sino Biopharma
• HUTCHMED

Recent Developments:In May 2023, Eli Lilly and Company received FDA approval for CYRAMZA® for treating advanced NSCLC patients with specific genetic mutations.In April 2023, Amneal Pharmaceuticals gained FDA approval for ALYMSYS, a bevacizumab biosimilar to Avastin, marking its third licensed biosimilar in the U.S.

Conclusion

The global Anti-VEGF market is poised for steady expansion through 2032, fueled by the increasing burden of cancer and ocular disorders, along with the growing preference for targeted therapies. While high treatment costs and side effects present some challenges, innovations in biologics, regulatory support for biosimilars, and rising healthcare investments in emerging regions are expected to unlock new growth avenues. As major players strengthen their pipelines and develop more cost-effective, efficient solutions, the Anti-VEGF market is set to remain a crucial component of oncology and ophthalmology treatment landscapes in the coming decade.

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web:
https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.